dc.creator | Sanchez Alberti, Andrés | |
dc.creator | Bivona, Augusto Ernesto | |
dc.creator | Cerny, Natacha | |
dc.creator | Schulze, Kai | |
dc.creator | Weißmann, Sebastian | |
dc.creator | Ebensen, Thomas | |
dc.creator | Morales, Maria Celina | |
dc.creator | Padilla, Ángel M. | |
dc.creator | Cazorla, Silvia Ines | |
dc.creator | Tarleton, Rick L. | |
dc.creator | Guzmán, Carlos A. | |
dc.creator | Malchiodi, Emilio Luis | |
dc.date.accessioned | 2018-04-04T16:11:07Z | |
dc.date.accessioned | 2022-10-15T11:08:22Z | |
dc.date.available | 2018-04-04T16:11:07Z | |
dc.date.available | 2022-10-15T11:08:22Z | |
dc.date.created | 2018-04-04T16:11:07Z | |
dc.date.issued | 2017-02 | |
dc.identifier | Sanchez Alberti, Andrés; Bivona, Augusto Ernesto; Cerny, Natacha; Schulze, Kai; Weißmann, Sebastian; et al.; Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection; Nature Publishing Group; Nature Vaccines; 2; 1; 2-2017; 1-12 | |
dc.identifier | 2059-0105 | |
dc.identifier | http://hdl.handle.net/11336/40702 | |
dc.identifier | CONICET Digital | |
dc.identifier | CONICET | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/4379097 | |
dc.description.abstract | The parasite Trypanosoma cruzi is the causative agent of Chagas disease, a potentially life-threatening infection that represents a major health problem in Latin America. Several characteristics of this protozoan contribute to the lack of an effective vaccine, among them: its silent invasion mechanism, T. cruzi antigen redundancy and immunodominance without protection. Taking into account these issues, we engineered Traspain, a chimeric antigen tailored to present a multivalent display of domains from key parasitic molecules, combined with stimulation of the STING pathway by c-di-AMP as a novel prophylactic strategy. This formulation proved to be effective for the priming of functional humoral responses and pathogen-specific CD8+ and CD4+ T cells, compatible with a Th1/Th17 bias. Interestingly, vaccine effectiveness assessed across the course of infection, showed a reduction in parasite load and chronic inflammation in different proof of concept assays. In conclusion, this approach represents a promising tool against parasitic chronic infections. | |
dc.language | eng | |
dc.publisher | Nature Publishing Group | |
dc.relation | info:eu-repo/semantics/altIdentifier/url/http://www.nature.com/articles/s41541-017-0010-z | |
dc.relation | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1038/s41541-017-0010-z | |
dc.rights | https://creativecommons.org/licenses/by/2.5/ar/ | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Chagas Disease | |
dc.subject | Immunogen | |
dc.subject | Quimera | |
dc.subject | C-Di-Amp | |
dc.title | Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:ar-repo/semantics/artículo | |
dc.type | info:eu-repo/semantics/publishedVersion | |